anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a plant active composition for drug-free breeding and a preparation method thereof. According to the preparation method, medicinal materials such as isatis root, coptis, lithospermum, haw and licorice, etc. are mainly used; each medicinal material respectively passes through water, ethanol and an ethyl acetate solvent for extraction; each medicinal material is concentrated and mixed to obtain an extract product of each medicinal material; and the medicinal materials can be firstly mixed and then extracted, or the medicinal materials are firstly extracted and then mixed. Thus, the plant active composition is obtained. In addition, the plant active composition also can be used along with dandelion, Radix Astragali or probiotics. Bacteriostatic plant active components are used, and combination ratio of extracted plant active composition is adjusted. Then, the plant active composition has synergistic interaction effects. By the use of the plant active composition, immunity of animals can be raised, feed conversion ratio is good, and a natural drug-free health breeding condition is provided.
The invention provides a multi-moisturizing double-layer makeup remover. The multi-moisturizing double-layer makeup remover is characterized by being prepared from, by weight, 20%-35% of grease, 1%-15% of alcohol moisturizer, 0.25%-2.5% of sugar moisturizer, 0.01%-0.25% of macromolecular moisturizer, 5%-20% of surfactant, 0.25%-2.5% of natural moisturizing factors (NMF), 0.1%-0.6% of preservative, 0.1%-0.4% of anti-allergic agent and the balance deionized water. The double-layer makeup remover greatly integrates cleansing oil and cleansing water and adopts an oil-water separation structure, the bottom layer is water, and the upper layer is oil. Before the makeup remover is used, the makeup remover is needed to be shaken to be uniform, the water-oil proportion is adjusted to reach the state that the makeup remover is non-irritant to the skin, the advantage of string makeup removing capability of the cleansing oil is played, and a mild and non-irritant effect is also achieved. In addition, the composite moisturizing system formed by four different types of moisturizing components serves as a whole, the defect that single moisturizing components are not comprehensive and not remarkable in effect is greatly overcome. Furthermore, the invention further provides a preparation method of the multi-moisturizing double-layer makeup remover.
Comprising children diagnosed with Type 1 Diabetes Mellitus (T1DM). This group constitutes the focal point of the study, assessing the motor and sensory functions of the hand. These children undergo various tests and measurements aimed at evaluating the motor skills, sensory perception, and functionality of the hand. The study solely involves evaluation and will not include any treatment or intervention.
PURPOSE: To prepare a nourishing supplementing agent, comprising a lithium compound and capable of controlling a morbid state caused by deficiency in essential minerals. CONSTITUTION: This nourishing supplementing agent comprises a physiologically permissible lithium compound therein. The lithium compound is a lithium salt selected from lithium carbonate, lithium citrate, lithium chloride, lithium succiniate, lithium sulfate, lithium salicylate, lithium acetylsalicylate and lithium orotate. The agent can be prepared as the form of a parenteral or an enteric nourishing liquid solution. The lithium compound is preferably mixed with four or more kinds of vitamins or minerals and a carrier or an excipient, as necessary, is added thereto. The lithium content in the nourishing supplementing agent is 1ppb to 30% expressed in terms of weight and the daily dose for an adult is 1μg to 50mg.
This is a randomized, controlled cross-over trial. The hypothesis of this study is that the different extubation protocol can impact recovery quality in children in post-anaesthesia care unit (PACU). Patients aged 3-7 years were randomized into two equal groups: proactive extubation (Group A) and passive extubation. At the end of surgery, sevoflurane was turned off and patients all delivered into PACU for recovery. Patient was positioned on his or her lateral side. The ventilation was switched to positive airway pressure (CPAP) mode once the patients regained spontaneous respiration. After spontaneous breathing turn to regular and sufficient（tidal volume \>6-8 ml/kg, respiratory rate \>10 times per minutes , end tidal carbon dioxide concentration \>7.19 mmHg）, the trachea tube could be removed. In Group A, patients were extubated in a light plane of anesthesia, when they are still asleep or have swallowing reflex. In Group B, tracheal extubation was performed when the patient regained consciousness, facial grimace, spontaneous eye opening, and purposeful arm movement. After extubation, 2 L/min oxygen was administered with Venturi face mask for 10 min in both groups. Patients were transported to the ward until they breathed air with a patent airway. The extubation time, recovery characteristics and respiratory complication were recorded.
The invention discloses a body composition automatic measuring system based on abdominal CT images and deep learning. The system comprises a positioning module for all axial slices corresponding to the third lumbar vertebra on a CT image, a four-class skeletal muscle segmentation module for axial slices corresponding to the third lumbar vertebra on the CT image, and an automatic body composition measurement module based on the CT image. The first two modules are utilized to train a deep learning model to position and segment four skeletal muscles of the third lumbar vertebra, and the proportion of body components such as fat, muscle and the like is automatically calculated. The invention is trained and verified on CT data of clinical liver cirrhosis patients, the average Dice of the four skeletal muscle segmentation results is 0.9283, and the average surface distance is 0.6779 mm. The present invention can also obtain body components such as subcutaneous fat and intra-abdominal fat by threshold treatment. The time for obtaining the body components corresponding to the third lumbar vertebra in batches is 2-3 seconds, and the method has important significance for clinically diagnosing complications of liver cirrhosis patients.
PURPOSE: A pack for preventing striae distensae of pregnant women with a surface sheet containing nutritive components, a cut-out part, and a protection film is provided to minimize nutrient loss, to absorb the nutritive components into skin, and to ensure excellent adhesion. CONSTITUTION: A pack(10) for preventing striae distensae of pregnant women contains a surface sheet(100) and nutritive components(200). The surface sheet comes in contact with skin. The nutritive components are applied on one side or both sides of the surface sheet and supplies moisture and nutrient into skin. The pack also has two or more cut-out parts and a protection film. The protection film is coated on the other side of the surface sheet and maintains moisturization.
This is a single-arm study. Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.
This is a pilot, single-group, interventional, prospective study including patients with moderate Alzheimer's disease, treated with galantamine. Galantamine is thought to benefit the cognitive functioning of those with Alzheimer's disease. The starting treatment dose is 8 mg/day for 4 weeks. The initial maintenance dose of galantamine is 16 mg/day. Patients should be maintained on 16 mg/day for 4 weeks. An increase to the maintenance dose of 24 mg/day should be considered on an individual basis after the appropriate assessment including evaluation of clinical benefit and tolerability. For individual patients not showing an increased response or not tolerating 24 mg/day, a dose reduction to 16 mg/day should be considered. The primary objective is the assessment of the modulating effect of galantamine (Reminyl PRC) on circadian rhythm (wake/sleep) in patients with moderate Alzheimer's disease. The secondary objective is to assess the perception of the physicians, caregivers and patients themselves on sleep-wake disorders in patients with moderate Alzheimer's disease before and after treatment with galantamine. Sleep disturbances will be assessed by two actigraphy measures: one, before starting treatment, and the other, 12 weeks after the first actigraphic measure. The primary endpoint is the day/night ratio measured by the actigraphy before and after treatment with galantamine in patients with moderate Alzheimer-type dementia. Concerning the Efficacy Measures, the Actigraphy will be used as a method to assess the modulating effect of galantamine on circadian rate. The impact of this modulating effect on the caregivers, patients themselves and physicians will be assessed by three questionnaires: the Zarit Caregiver Burden Interview (ZBI), the Pittsburgh Sleep Quality Index (PSQI) and the Clinical Global Impression (CGI), respectively. Patient safety will be monitored. It is estimated that the study period will range from September 2010 to the second quarter of 2011.
Myocardial dysfunction is a prevalent complication of sepsis (septic cardiomyopathy) with a high mortality rate and limited therapeutic options. Naringenin, a natural flavonoid compound with anti-inflammatory and antioxidant properties, holds promise as a potential treatment for sepsis-induced myocardial dysfunction. This study investigated the pharmacological effects of naringenin on septic cardiomyopathy. In vivo and in vitro experiments demonstrated that naringenin improved cardiomyocyte damage. Network pharmacology and database analysis revealed that HIF-1α is a key target protein of naringenin. Elevated expression of HIF-1α was observed in damaged cardiomyocytes, and the HIF-1α inhibitor effectively protected against LPS-induced cardiomyocyte damage. Molecular docking studies confirmed the direct binding between naringenin and HIF-1α protein. Importantly, our findings demonstrated that naringenin did not provide additional attenuation of cardiomyocyte injury on the biases of HIF-1α inhibitor treatment. In conclusion, this study proves that naringenin protects against septic cardiomyopathy through HIF-1α signaling. Naringenin is a promising therapeutic candidate for treating septic cardiomyopathy.
This is a multicenter (when more than one hospital or medical school team work on a medical research study), randomized (the study drug is assigned by chance), open-label (all people know the identity of the intervention), comparative study to compare the efficacy of tramadol hydrochloride plus acetaminophen maintenance with that of NSAIDs maintenance in participants whose pain was relieved after the add-on treatment of tramadol 37.5 milligram (mg) plus acetaminophen 325 mg to NSAIDs. All participants will receive tramadol hydrochloride 37.5 mg plus acetaminophen 325 mg, 1 to 3 tablets per day along with NSAIDs (meloxicam \[7.5 mg or 15 mg once daily\] or aceclofenac \[100 mg twice daily\]) from Day 1 to Day 28, and participants will be randomly assigned into 2 treatment groups at Day 29 if the numerical rating scale score less than or equal 4. Tramadol plus acetaminophen group will receive 1 or 2 tablets containing tramadol 37.5 mg plus acetaminophen 325 mg 4 times daily (maximum daily dose will be 8 tablets) from Day 29 to Day 85 and NSAIDs group will receive either meloxicam 7.5 mg or 15 mg per day or aceclofenac 100 mg twice a day from Day 29 to Day 85. The efficacy will be evaluated on Day 1, Day 29, Day 57 and Day 85. The primary efficacy end point will be assessed through change in Western Ontario McMaster Universities Osteoarthritis Index (WOMAC) total score from Day 29 to Day 85. Participant's safety will be monitored throughout the study.
OBJECTIVES: In axial spondyloarthritis (axSpA), early diagnosis is crucial, but diagnostic delay remains long and diagnostic criteria do not exist. We aimed to identify a diagnostic model that distinguishes patients with axSpA from patients without axSpA with chronic back pain based on clinical data in routine care.
METHODS: Clinical data from patients with chronic back pain were used, with information on rheumatological examinations based on clinical indications. The total dataset was randomly divided into training and test datasets at a 7:3 ratio. A machine learning-based model was built to distinguish axSpA from non-axSpA using the random forest algorithm. Overall accuracy, sensitivity, specificity and the area under the receiver operating characteristic curve-area under the curve (ROC-AUC) in the test dataset were calculated. The contribution of each variable to the accuracy of the model was assessed.
RESULTS: Data from 939 randomly selected patients were available: 659 diagnosed with axSpA and 280 with non-axSpA. In the test dataset, the model reached an accuracy of 0.9234, a sensitivity of 0.9586, a specificity of 0.8438 and a ROC-AUC of 0.9717. Human leucocyte antigen B27 (HLA-B27) contributed most to the accuracy of the model; that is, the accuracy would suffer most from not using HLA-B27, followed by insidious onset of back pain and erosions in the sacroiliac joint.
CONCLUSIONS: We provide a machine learning-based model that reveals high performance in diagnosing patients with chronic back pain with axSpA versus without axSpA based on information from a tertiary rheumatology practice. This model has the potential to improve diagnostic delay in patients with axSpA in daily routine settings.
The safety and effectiveness of atorvastatin calcium as an adjunct to diet to reduce LDL-C have been established pediatric patients 10 years of age and older with HeFH. Use of atorvastatin calcium for this indication is based on a double-blind, placebo-controlled clinical trial in 187 pediatric patients 10 years of age and older with HeFH. In this limited controlled trial, there was no significant effect on growth or sexual maturation in the males or females or on menstrual cycle length in females. 

The safety and effectiveness of atorvastatin calcium as an adjunct to other LDL-C-lowering therapies to reduce LDL-C have been established pediatric patients 10 years of age and older with HoFH. Use of atorvastatin calcium for this indication is based on a trial without a concurrent control group in 8 pediatric patients 10 years of age and older with HoFH [see Clinical Studies (14)]. 

The safety and effectiveness of atorvastatin calcium tablets have not been established in pediatric patients younger than 10 years of age with HeFH or HoFH, or in pediatric patients with other types of hyperlipidemia (other than HeFH or HoFH).
PCT No. PCT/US96/13764 Sec. 371 Date Apr. 29, 1997 Sec. 102(e) Date Apr. 29, 1997 PCT Filed Aug. 27, 1996 PCT Pub. No. WO97/07776 PCT Pub. Date Mar. 6, 1997The invention relates to substantially dust-free bleach powders that, when mixed with aqueous hydrogen peroxide, yield activated bleach compositions that exhibit improved thixotropy. The bleach powders comprise at least one de-dusting agent and at least one peroxygenated salt. The de-dusting agents, which are preferably present in an amount less than about 10% by weight of the bleach powder are inert, substantially hydrophilic compounds selected from alkylated esters, cyclic ethers and cyclic esters. The bleach powders also comprise powdered polytetrafluoroethylene (PTFE) in an amount of about 1-5% by weight of the bleach powder. The bleach powders also comprise an ammonia source, e.g., an ammonium halide, diammonium phosphate, ammonium sulfate and mixtures thereof. Optionally, one or more hair conditioning agents, thickeners and desiccants may be added to the dust-free bleach powder.
FOLFOX/Bevacizumab will be given for 4 cycles over 8 weeks; FOLFOLX6 without Bevacizumab will be given for an additional 2 cycles over 4 weeks. Oxaliplatin will be given on Day 1 of each cycle over 2 hours at 85 mg/m2 IV. Leucovorin will be given Day 1 of each cycle over 2 hours at 400 mg/m2 IV. Fluorouracil will be given on Day 1 of each cycle at 400 mg/m2 IVP, then Fluorouracil will be given at 1200 mg/m2 IVCI over Day 1 and 2. Bevacizumab will be given at 5mg/kg over 10 minutes on day 1. Patients will undergo re-staging within 3 weeks of completing their 6th cycle of FOLFOX. If the reassessment reveals that there has been no disease progression as compared to the pre-treatment evaluation and the patient remains a candidate for an R0 resection. If the surgical oncologist's reassessment is that the patient is not a candidate for an R0 resection, the patient will proceed to standard pre-operative radiation with synchronous infusional 5-fluorouracil.
Behavioral treatment is implemented in 4 clinic visits over a period of 6 weeks, followed by 6 weeks of combined behavioral + drug therapy. Behavioral treatment consists of behavioral training and includes skills and strategies for postponing urination, controlling urgency and preventing urge incontinence. This includes pelvic floor muscle training, incremental delayed voiding, and daily bladder diaries, supplemented with instructions for daily home practice between clinic visits. In addition to daytime training, nocturia is managed with fluid restriction (3 hours before bedtime and during the night) and with urge strategies.
Two SC injections of Alirocumab 150 mg Q4W alternating with two SC injections of placebo Q4W with or without stable statin therapy for 48 weeks. Alirocumab dose up-titrated to 150 mg from Week 12 when LDL-C levels ≥ 70 mg/dL (1.81 mmol/L) (for very high CV risk participants) or ≥ 100 mg/dL (2.59 mmol/L) (for moderate and high CV risk participants) at Week 8.
Isorhamnetin has recently been found to exhibit a remarkable anti-motion sickness effect, yet the underlying mechanism is still unclear. Herein, network pharmacology was employed to conduct a preliminary analysis on the possible biological processes involved. Results showed that common targets were localized in membranes, mitochondria, and glutamatergic synapses. In particular, protein phosphorylation, protein serine/threonine/tyrosinase activity and signal transduction might play a role in isorhamnetin's anti-motion sickness effect. Thus, mice phosphoproteomics analysis was further performed to explore the phosphorylated protein changes in the motion sickness process. Results showed that differentially phosphorylated proteins have an effect on postsynaptic density, glutamatergic synapses and other sites and are involved in various neurodegenerative disease pathways, endocytic pathways, cAMP signaling pathways and MAPK signaling pathways. Two key differentially phosphorylated proteins in glutamatergic synapses, namely, DLGAP and EPS8, might play key roles in isorhamnetin's anti-motion sickness process. The final molecular experimental verification results from qRT-PCR and western blot analyses indicated that isorhamnetin firstly regulates glutamatergic synapses and then reduces the excitability of the vestibular nucleus through inhibiting the NMDAR1/CaMKII/CREB signaling pathway, ultimately alleviating a series of symptoms of motion sickness in mice. The findings of this study provide valuable insights and a useful theoretical basis for the application of isorhamnetin as a new anti-motion sickness food ingredient.
Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) has been reported in patients taking NSAIDs such as ZIPSOR. Some of these events have been fatal or life-threatening. DRESS typically, although not exclusively, presents with fever, rash, lymphadenopathy, and/or facial swelling. Other clinical manifestations may include hepatitis, nephritis, hematological abnormalities, myocarditis, or myositis. Sometimes symptoms of DRESS may resemble an acute viral infection. Eosinophilia is often present. Because this disorder is variable in its presentation, other organ systems not noted here may be involved. It is important to note that early manifestations of hypersensitivity, such as fever or lymphadenopathy, may be present even though rash is not evident. If such signs or symptoms are present, discontinue ZIPSOR and evaluate the patient immediately.
A computer-implemented system and method for real-time feedback collection and analysis is provided. A location of a patient associated with an RFID tag is monitored. A space occupied by the patient is determined based on the location and one or more prompts for feedback are identified based on the occupied space. At least one of the prompts is provided to the patient. Feedback is received from the patient in response to the prompt. The received feedback is analyzed.
PURPOSE:To enhance the temp. stability and usability of a composition in a water in oil type emulsified composition useful as cosmetics or medicines, by using water-swellable clay mineral, a nonionic surfactant, an oil component and water as essential components. CONSTITUTION:A water in oil type (hereinbelow referred to as a W/O type) emulsion is prepared by compounding 0.2-5% or water-swellable clay mineral being one kind of colloidal aluminum silicate hydrate having a three-layered structure and 0.05-2 times by wt. of the water swellable clay mineral of a nonionic surfactant. An oil component can be widely adapted from polar oil to non-polar oil and compounded in an amount of 5-90wt% of the W/O type emulsion. In preparing a composition, for example, the water-swellable clay mineral, the oil component and the nonionic surfactant are mixed at about 70 deg.C under heating and stirring and an aqueous phase is added to the resulting mixture while stirring to prepare the emulsion having excellent storage stability over a wide temp. range.
The investigators will conduct 11 pragmatic trials using the EMR: brain tumors (prevent seizures), epilepsy (prevent other seizure types), mild cognitive impairment (improve memory), migraine (prevention), migraine (abortive), mild traumatic brain injury (prevent post concussion syndrome), multiple sclerosis (attenuate relapses), neuropathy (pain management), Parkinson's (treat motor symptoms), restless legs syndrome (treat sensory symptoms), stroke (secondary prevention). For each trial they will compare up to three medications or treatments either FDA approved for the indication, or commonly employed. The pragmatic trials will be small and primarily to demonstrate the feasibility of subgroup based adaptive assignment of treatments, electronic consenting, and data capture at the point of care using the EMR. The focus is on the development of the study design and methodology and not on the treatments per se.
OZEMPIC has been studied as monotherapy and in combination with metformin, metformin and sulfonylureas, metformin and/or thiazolidinedione, and basal insulin in patients with type 2 diabetes mellitus. The efficacy of OZEMPIC was compared with placebo, sitagliptin, exenatide extended-release (ER), and insulin glargine. 

Most trials evaluated the use of OZEMPIC 0.5 mg, and 1 mg, with the exception of the trial comparing OZEMPIC and exenatide ER where only the 1 mg dose was studied. One trial evaluated the use of OZEMPIC 2 mg once weekly.

In patients with type 2 diabetes mellitus, OZEMPIC produced clinically relevant reduction from baseline in HbA1c compared with placebo.

The efficacy of OZEMPIC was not impacted by age, gender, race, ethnicity, BMI at baseline, body weight (kg) at baseline, diabetes duration and level of renal function impairment.